269 related articles for article (PubMed ID: 27267856)
1. An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients.
Piro G; Carbone C; Cataldo I; Di Nicolantonio F; Giacopuzzi S; Aprile G; Simionato F; Boschi F; Zanotto M; Mina MM; Santoro R; Merz V; Sbarbati A; de Manzoni G; Scarpa A; Tortora G; Melisi D
Clin Cancer Res; 2016 Dec; 22(24):6164-6175. PubMed ID: 27267856
[TBL] [Abstract][Full Text] [Related]
2. Resistance Mechanism against Trastuzumab in HER2-Positive Cancer Cells and Its Negation by Src Inhibition.
Jin MH; Nam AR; Park JE; Bang JH; Bang YJ; Oh DY
Mol Cancer Ther; 2017 Jun; 16(6):1145-1154. PubMed ID: 28223426
[TBL] [Abstract][Full Text] [Related]
3. Dual PI3K/mTOR inhibitor BEZ235 exerts extensive antitumor activity in HER2-positive gastric cancer.
Zhu Y; Tian T; Zou J; Wang Q; Li Z; Li Y; Liu X; Dong B; Li N; Gao J; Shen L
BMC Cancer; 2015 Nov; 15():894. PubMed ID: 26560145
[TBL] [Abstract][Full Text] [Related]
4. Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop.
Yang Z; Guo L; Liu D; Sun L; Chen H; Deng Q; Liu Y; Yu M; Ma Y; Guo N; Shi M
Oncotarget; 2015 Mar; 6(7):5072-87. PubMed ID: 25669984
[TBL] [Abstract][Full Text] [Related]
5. miR-200c inhibits TGF-β-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer.
Zhou X; Men X; Zhao R; Han J; Fan Z; Wang Y; Lv Y; Zuo J; Zhao L; Sang M; Liu XD; Shan B
Cancer Gene Ther; 2018 May; 25(3-4):68-76. PubMed ID: 29302045
[TBL] [Abstract][Full Text] [Related]
6. Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.
Zuo Q; Liu J; Zhang J; Wu M; Guo L; Liao W
Sci Rep; 2015 Jun; 5():11634. PubMed ID: 26108989
[TBL] [Abstract][Full Text] [Related]
7. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
8. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
9. Label-Free Quantitative Proteomics Combined with Biological Validation Reveals Activation of Wnt/β-Catenin Pathway Contributing to Trastuzumab Resistance in Gastric Cancer.
Liu W; Yuan J; Liu Z; Zhang J; Chang J
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29986466
[TBL] [Abstract][Full Text] [Related]
10. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
11. The ErbB2-targeting antibody trastuzumab and the small-molecule SRC inhibitor saracatinib synergistically inhibit ErbB2-overexpressing gastric cancer.
Han S; Meng Y; Tong Q; Li G; Zhang X; Chen Y; Hu S; Zheng L; Tan W; Li H; Chen Y; Zhang G; Li B; Guo Y
MAbs; 2014; 6(2):403-8. PubMed ID: 24492292
[TBL] [Abstract][Full Text] [Related]
12. HER2-targeted gold nanoparticles potentially overcome resistance to trastuzumab in gastric cancer.
Kubota T; Kuroda S; Kanaya N; Morihiro T; Aoyama K; Kakiuchi Y; Kikuchi S; Nishizaki M; Kagawa S; Tazawa H; Fujiwara T
Nanomedicine; 2018 Aug; 14(6):1919-1929. PubMed ID: 29885899
[TBL] [Abstract][Full Text] [Related]
13. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
[TBL] [Abstract][Full Text] [Related]
14. Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
Matsui Y; Inomata M; Tojigamori M; Sonoda K; Shiraishi N; Kitano S
Int J Oncol; 2005 Sep; 27(3):681-5. PubMed ID: 16077916
[TBL] [Abstract][Full Text] [Related]
15. MMP7 Induces T-DM1 Resistance and Leads to the Poor Prognosis of Gastric Adenocarcinoma
Li H; Xu X; Liu Y; Li S; Zhang D; Meng X; Lu L; Li Y
Anticancer Agents Med Chem; 2018; 18(14):2010-2016. PubMed ID: 30501604
[TBL] [Abstract][Full Text] [Related]
16. miR-301a-3p induced by endoplasmic reticulum stress mediates the occurrence and transmission of trastuzumab resistance in HER2-positive gastric cancer.
Guo J; Zhong X; Tan Q; Yang S; Liao J; Zhuge J; Hong Z; Deng Q; Zuo Q
Cell Death Dis; 2021 Jul; 12(7):696. PubMed ID: 34257270
[TBL] [Abstract][Full Text] [Related]
17. [Correlation between cyclin-dependent kinase inhibitor p27kip1 and trastuzumab-resistance in gastric cancer].
Wu M; Guo L; Zuo Q
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 May; 41(5):471-6. PubMed ID: 27269920
[TBL] [Abstract][Full Text] [Related]
18. C-Type Lectin-Like Receptor 2 Suppresses AKT Signaling and Invasive Activities of Gastric Cancer Cells by Blocking Expression of Phosphoinositide 3-Kinase Subunits.
Wang L; Yin J; Wang X; Shao M; Duan F; Wu W; Peng P; Jin J; Tang Y; Ruan Y; Sun Y; Gu J
Gastroenterology; 2016 May; 150(5):1183-1195.e16. PubMed ID: 26855187
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab-Resistant HER2
Wielgos ME; Zhang Z; Rajbhandari R; Cooper TS; Zeng L; Forero A; Esteva FJ; Osborne CK; Schiff R; LoBuglio AF; Nozell SE; Yang ES
Mol Cancer Ther; 2018 May; 17(5):921-930. PubMed ID: 29592880
[TBL] [Abstract][Full Text] [Related]
20. PTEN loss is associated with a poor response to trastuzumab in HER2-overexpressing gastroesophageal adenocarcinoma.
Deguchi Y; Okabe H; Oshima N; Hisamori S; Minamiguchi S; Muto M; Sakai Y
Gastric Cancer; 2017 May; 20(3):416-427. PubMed ID: 27517839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
